Docebo (DCBO) Research & Development (2019 - 2026)

Docebo (DCBO) has reported Research & Development for 8 consecutive years, with $15.5 million the latest figure, recorded in Q1 2026.

• Quarterly Research & Development rose 15.32% year-over-year to $15.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.2 million (up 11.25% YoY) and the FY2025 annual result came in at $50.1 million, up 14.15% from the prior year.
• Research & Development climbed to $15.5 million in Q1 2026 per DCBO's latest filing, from $12.1 million in the prior quarter.
• Over the last five years, Research & Development for DCBO reached as high as $15.5 million in Q1 2026 and fell as low as $6.1 million in Q3 2022.
• A 5-year average of $10.0 million and a median of $10.4 million in 2024 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2023 — Research & Development jumped 68.24% — and 2025, when it rose 4.63%.
• Year by year, Research & Development stood at $6.4 million in 2022, then soared by 41.49% to $9.0 million in 2023, then increased by 28.31% to $11.6 million in 2024, then gained by 4.63% to $12.1 million in 2025, then gained by 27.61% to $15.5 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $15.5 million, $12.1 million, and $11.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.